| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 广州安必平医药科技股份有限公司（股票代码：688393）成立于2005年，是国内病理诊断领域首家上市公司，集研发、生产、市场、服务、教育五位一体，构建了肿瘤筛查、肿瘤诊断、数智病理、病理服务四大业务，服务全国2200多家医疗机构。 安必平专注于肿瘤筛查与精准诊断，围绕医院病理科“标准化、自动化、数字化、智能化”的四化建设，自主研发了常规病理、液基细胞学（LBP）、聚合酶链式反应（PCR）、免疫组织化学（IHC）、荧光原位杂交（FISH）、数字病理等技术平台的配套设备、试剂耗材，注册/备案产品数量超700个，是国内病理产品线最齐全、最丰富的企业之一。 安必平积极响应国家政策号召，为解决病理行业人才匮乏、基层医院病理能力薄弱、降低大病医疗成本的等发展难题，充分利用在病理诊断领域的深厚积累，以“产品+服务”的双轮驱动模式，在夯实技术积累、加强产品创新的基础上，拓展了数字化智能化病理科建设、病理科能力提升、药企伴随诊断三大战略业务，用实际行动推动病理行业高质量发展。 安必平始终坚持“为社会和客户创造价值，以实现员工和企业价值”，致力于成为病理诊断领域的领先企业，用精准医学诊断造福社会。 | ||||||||||||||||||||||||
| Main Business | 病理诊断试剂和仪器的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 蔡向挺 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 侯全能 | ||||||||||||||||||||||||
| Solicitors | 广东信达律师事务所 | ||||||||||||||||||||||||
| Auditors | 中汇会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 020-32299997-8118;020-32210051 | ||||||||||||||||||||||||
| Fax No | 020-32290284 | ||||||||||||||||||||||||
| Website | www.gzlbp.com | ||||||||||||||||||||||||
| zqswb@gzlbp.com;dukun@gzlbp.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 20/08/2020 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.430 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.150 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 13.505 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.927B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |